Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101539 | 0.83 | — | — | |
| SCHEMBL9248005 | 0.80 | DNM1 (0.33) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL9248004 | 0.80 | DNM1 (0.33) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL1410188 | 0.77 | TSHR (0.50) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL28153757 | 0.77 | DNM1 (0.35) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL24914687 | 0.77 | DNM1 (0.35) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL18629455 | 0.77 | DNM1 (0.35) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL1285427 | 0.77 | TSHR (0.36) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL3185161 | 0.76 | DNM1 (0.47) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 | |
| SCHEMBL22345156 | 0.76 | DNM1 (0.47) | DNM1TSHRSMN1; SMN2OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | claimed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | claimed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | claimed |
| EP-0004172-B1 | BENZOCYCLOHEPTAPYRANS, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1982-04-07 | — | — | EP | claimed |
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| US-9809521-B2 | Cannabidinoid derivatives | SUTTER WEST BAY HOSPITALS (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2016-12-29 | — | — | US | disclosed |
| CN-103804687-B | Phenyl polysiloxane and preparation method thereof for high-power LED encapsulation | YANTAI DEBANG ADVANCED SILICON MATERIALS CO.,LTD. (CN) | 2016-05-11 | — | — | CN | disclosed |
| US-9254272-B2 | Resorcinol derivatives | SUTTER WEST BAY HOSPITALS (US) | 2016-02-09 | — | — | US | disclosed |
| US-9072917-B2 | Linear alkyl esters and their use in cosmetic and/or pharmaceutical compositions | COGNIS IP MANAGEMENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8642798-B2 | Silacycle compounds and methods of use thereof | THE TRUSTEE OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-02-04 | — | — | US | disclosed |
| EP-0004172-A1 | Benzocycloheptapyrans, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1979-09-19 | — | — | EP | disclosed |
| EP-0003883-A1 | Amino-dibenzopyrans, their preparation, formulations containing them and their use as pharmaceuticals | ELI LILLY AND COMPANY (US) | 1979-09-05 | — | — | EP | disclosed |
| US-4152450-A | 9-Amino-dibenzopyrans | ELI LILLY AND COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4152451-A | HYPOTENSIVE AGENTS | ELI LILLY AND COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4148809-A | Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones | ELI LILLY AND COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4140701-A | 2,6-Methano-2H-1-benzoxocins | ELI LILLY AND COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
| US-4131614-A | Process for preparing cis-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4102902-A | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | CNR1, CNR2, RCOR1 | DNM1 2342/4885TSHR 3290/4885SMN1; SMN2 4124/4885 |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | DNM1 1228/4885TSHR 4095/4885SMN1; SMN2 1784/4885 |
| US-20160376211-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | DNM1 1228/4885TSHR 4095/4885SMN1; SMN2 1784/4885 |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | CNR1, CNR2, RCOR1 | DNM1 2342/4885TSHR 3290/4885SMN1; SMN2 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.